Tech Company Financing Transactions

Tridek-One Funding Round

Pureos Bioventures, AdBio Partners and Advent Life Sciences joined a $16 million funding round for Tridek-One. The funding round closed on 9/16/2022.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

4, Rue Thénard
Paris, 75005
FR

Phone

+33 1 6 88 46 75 96

Website

www.tridekone.com

Email Address

[email protected]

Overview

Tridek-One is a private biotechnology company founded in 2018, based on groundbreaking research by our scientific founders at INSERM, Paris on the role of CD31 in the modulation of the immune response. CD31 belongs to a family of receptors harboring immunoreceptor tyrosine-based inhibitory motifs?(ITIMs). Developing agonists for 'ITIM receptors' has the potential to restore the immune balance without immunosuppression.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Laurence Schoulepnikoff

        

Chief Financial Officer

Régis Olivier

        

Browse more venture capital transactions:

Prev: 9/16/2022: Builders venture capital transaction
Next: 9/16/2022: Satschel venture capital transaction

Share this article

About Our Venture Capital Transactions Database

Our team works diligently to document every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary